Last reviewed · How we verify
CV-18C3
At a glance
| Generic name | CV-18C3 |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis. (PHASE2)
- A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (PHASE3)
- Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CV-18C3 CI brief — competitive landscape report
- CV-18C3 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI